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Abstract
Magnetic Resonance-guided radiotherapy (MRgRT) marks the beginning of a new era. MR is a versatile and suitable
imaging modality for radiotherapy, as it enables direct visualization of the tumor and the surrounding organs at risk.
Moreover, MRgRT provides real-time imaging to characterize and eventually track anatomical motion. Nevertheless,
the successful translation of new technologies into clinical practice remains challenging. To date, the initial
availability of next-generation hybrid MR-linac (MRL) systems is still limited and therefore, the focus of the present
preview was on the initial applicability in current clinical practice and on future perspectives of this new technology
for different treatment sites.
MRgRT can be considered a groundbreaking new technology that is capable of creating new perspectives towards
an individualized, patient-oriented planning and treatment approach, especially due to the ability to use daily
online adaptation strategies. Furthermore, MRL systems overcome the limitations of conventional image-guided
radiotherapy, especially in soft tissue, where target and organs at risk need accurate definition. Nevertheless, some
concerns remain regarding the additional time needed to re-optimize dose distributions online, the reliability of the
gating and tracking procedures and the interpretation of functional MR imaging markers and their potential
changes during the course of treatment. Due to its continuous technological improvement and rapid clinical large-
scale application in several anatomical settings, further studies may confirm the potential disruptive role of MRgRT
in the evolving oncological environment.
Keywords: MR-guided radiotherapy, Image-guided, radiotherapy, MR-IGRT, MR-Linac, adaptive radiotherapy, Inter-
fraction variability, Intra-fraction fraction variability, MRI, outcome
Introduction
Advanced radiation techniques, including intensity mo-
dulated radiation therapy (IMRT), volumetric modulated
arc therapy (VMAT) or high-dose stereotactic body
radiotherapy (SBRT) pursue the goal of delivering high
doses to the tumor, while sparing the surrounding
tissues and organs at risk (OARs). To ensure a precise
dose delivery, image-guided radiotherapy (IGRT) has been
developed and widely introduced into clinical practice.
Current IGRT techniques using on-board cone-beam CT
(CBCT) are already very effective, but are limited due to
the reduced soft-tissue contrast. Frequently, it remains
challenging to distinguish tumor from normal tissues,
with the consequence that dose escalation strategies are
not readily feasible, or generous planning target volume
(PTV) margins are applied to account for uncertainties in
gross tumor volume (GTV) delineation, dose delivery and
target coverage.
On-board real-time Magnetic Resonance Imaging
(MRI)-guided radiotherapy (MRgRT) with hybrid MR-
linear accelerator (MRL) systems marks the beginning of
a new era. MRI is the most versatile and suitable
imaging modality for RT, as it provides direct visualization
of the tumor and surrounding tissue anatomy. Moreover,
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it provides real-time imaging to characterize and eventu-
ally track anatomical motion. Respiratory gating by MRI is
particularly advantageous in several aspects for high dose
SBRT [1, 2]. It enables motion mitigation and a reduction
of PTV margins and allows for an accurate dose delivery
to the PTV by reducing dose exposure of OARs. Certain
anatomical sites or specific organs affected by motion
from different sources (e.g. breathing, bowel displacement
/bladder filling) may benefit from MR-guided gating tech-
niques: thoracic tumors, including lung or mediastinal
lesions, breast cancer, and abdominal or pelvic tumors,
such as liver or pancreatic lesions and prostate cancer.
Moreover, real-time plan adaptation, while the patient is
on the treatment table, is a disruptive concept of the
innovative MR-linear accelerator (MRL) workflow [3]. This
new key feature will allow physicians to optimize dose
escalation strategies, as there is a further potential for
reducing dose to OARs, especially when a precise
localization and real-time tracking of the tumor is ensured.
Clinical sites
Successful translation of new technologies into clinical
practice remains challenging. To date, the initial avail-
ability of next-generation hybrid MR-linac systems is still
limited and therefore, the focus of the present preview is
on the initial applicability in current clinical practice and
on future perspectives of this new technology for diffe-
rent treatment sites.
Brain
Tumors of the central nervous system (CNS) are fre-
quently treated with RT. Specific entities are metastases,
primary brain tumors (low-grade gliomas, anaplastic as-
trocytomas, oligodendrogliomas, glioblastomas), extra-
axial tumors such as meningioma, and other benign
entities including pituitary adenomas and vestibular
schwannomas. A MRI-based planning workflow could
potentially be both, cost- and time-saving while reducing
uncertainties associated with CT-MRI registration [4].
MRI already represents the gold-standard imaging
method for brain tumor diagnosis and the assessment of
treatment response [5]. In this context, MRgRT allows for
the first time to obtain both, structural and functional
information during RT and to manage the adaptation
of the prescribed dose during the treatment, in order
to optimize outcome. To date, in daily clinical prac-
tice, a recent MRI is usually co-registered to bony
structures of a simulation CT, achieving a high degree
of confidence. Thus, due to these consolidated pro-
cedures, RT is already commonly delivered with a
high level of precision to brain targets. Therefore, as
well as hypothesized after the introduction of PET-MRI, a
lot of concerns could be related to the real usefulness of
MRgRT in brain RT.
However, a crucial difference emerges: the MRL sys-
tems enable a rapid adaptation, immediate target volume
delineation [6] and quick tumor response assessment.
An example is the treatment of a resection cavity, which
can change significantly in shape and size between the
simulation MRI and the initiation of treatment [4].
Furthermore, if hypofractionated stereotactic radiosurgery
(SRS) is applied, the resection cavity could also change
during the treatment course of 3–5 fractions, which would
be visible using MRgRT. Tseng and colleagues assessed
the dosimetric impact of the magnetic field, including the
electron return effect at tissue-air boundaries in SRS and
could show that neither target conformity nor dose
gradient were negatively impacted [7]. Moreover, Wen
and colleagues demonstrated, that excellent plan quality
and dose delivery accuracy was achievable on the MRL
system for treating multiple brain metastases with a single
isocenter [8]. Besides high-dose fractionation schemes, it
is expected that conventionally fractionated to moderately
hypofractionated schedules will represent the standard-of-
care in primary brain tumors due to improved therapeutic
ratios. Nevertheless, it remains unknown, which advan-
tages can result from the daily targeting and planning
optimization by MRgRT, since the available MRI se-
quences, which are currently still very limited, may be
improved in the future. To date, changes in gross tumor
volume (GTV) [9] would at least allow early adaptation of
the treatment plan.
In summary, MRgRT creates a new perspective towards
an individualized, patient-centric planning approach using
online adaptation for intracranial treatments. Further-
more, a significant increase in knowledge is expected
concerning the biological processes, which occur during
RT and its effect on patient survival for brain diseases.
Head & Neck
MRI is increasingly used in head and neck (H&N) RT
due to its superior soft tissue contrast and its versatility.
MRI is utilized in treatment planning to delineate the
GTV [10], the clinical target volume (CTV) [11] and to
estimate the necessary PTV margin [12] and to assess
the loco-regional treatment response [13]. Undoubtedly,
the advent of MRL [3] opens the door to fully exploit
the advantages of MRI over CBCT by its online adap-
tation capability during the treatment procedures (Fig. 1).
The following significant improvements are anticipated:
Adaptation to anatomical changes
During the course of irradiation, H&N patients can
significantly lose weight and OARs, such as the parotid
glands can dramatically shrink [14]. The time scale of
these changes does not require online optimization.
However, the MRL and its workflow are designed to
inherently manage these potential changes and online,
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offline or weekly adaptation can be applied for optimal
OAR sparing.
Adaptation to tumor response
Tumor response varies from significant volumetric
changes of large lymph nodes to more subtle MR signal
changes within the GTV. When the tumor clearly
shrinks and is replaced by healthy tissue, the GTV might
be adapted in a straightforward manner [15]. How to
adapt to MR signal intensity changes within the initial
GTV must be investigated in well-designed clinical trials.
For oropharyngeal cancer, a distinction should be pro-
posed between HPV positive patients, where dose de-
escalation could be considered for well-responding
GTVs, and HPV-negative patients that require dose
escalation to poor-responding regions inside the GTV.
Motion management
H&N cancer patients are treated using an immobilization
mask that, in combination with the several rigid bony
structures, minimize major intrafraction motion. However,
considerable motion has been observed for the larynx and
the tongue due to breathing, movement of the tongue and
swallowing [12]. Cine-MR during radiation can be applied
to guarantee minimal PTV margins. Furthermore, ex-
ception gating might be applied to interrupt irradiation in
case of excessive motion.
Curative treatment schemes for H&N cancer patients
usually consist of 30 to 35 fractions. Full online plan
optimization including the registration, adaptation,
optimization and QA steps currently takes approximately
45min [3] for relatively simple dose distributions. Never-
theless, thirty fractions of 45min in a noisy, claustropho-
bic environment is probably too distressing for many
patients. This discomfort might be reduced by developing
a quick MRL workflow when minimal adaptation is
needed, and apply full online adaptation only, when major
changes occur. Furthermore, comfortable patient position-
ing methods including noise reduction will be developed.
Both patient comfort and a reduced workflow are pre-
requisites to fully exploit the promises of MR-guidance for
head-and-neck cancer patients.
Lung
Non-small-cell lung cancer (NSCLC) histology accounts
for approximately 85% of all lung cancer cases. Of these,
almost 30% present with locally advanced disease, and RT
in combination with chemotherapy represents the treat-
ment of choice for this patient group [16–19]. Because of
the low survival rates, dose escalation strategies for stage
III NSCLC have been advocated [20, 21]. However, dose
escalation for stage III NSCLC requires caution and
should be thoroughly studied. Volumetric and positional
changes throughout the course of RT have been reported,
making adaptive irradiation for advanced lung cancer
necessary in about 1/3 of the patients to ensure target
coverage and reduce lung dose [22, 23]. Lung tumor
motion is complex and is dependent on the location of
the tumor in the lung and whether it is attached to rigid
structures, such as the chest wall or vertebrae. Motion
amplitudes of several centimeters have been reported in
the literature [24]. By direct visualization of the “real-time”
tumor position in combination with respiratory gated dose
delivery, an MR-guided treatment unit can offer a much
more accurate and precise dose delivery, without the use
of any surrogate or statistical model for respiration [1, 25].
SBRT is a well-established technique for the manage-
ment of stage I NSCLC, which has significantly improved
Fig. 1 Cone beam CT images of an oropharyngeal cancer patient (upper row) compared to the 1.5 T MR images (T1 3D 0.7 × 0.7 × 1.2 mm3) of
the same patient acquired at the MRL (lower row)
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local control (LC) in comparison to conventional fraction-
ation. LC rates of ≥85% are achieved when the prescribed
biologically equivalent tumor dose is ≥100 Gy [26–29]. It
is common practice to generate treatment volumes for
lung SBRT from 4D-CT acquisition [29, 30]. However, this
can lead in some instances to large treatment volumes
whereas MR-guided SBRT treatment delivery for lung
tumors has shown promising results in terms of treatment
volume reduction and intra-fraction motion management
[1, 2]. SBRT has also been shown to be an effective mo-
dality for treating patients after failure of conventional
irradiation and metastatic lung tumors, achieving good
local control with acceptable toxicity [31–35]. Recent
reports regarding online plan adaptation for SBRT treat-
ments under MR-guidance have shown promising results
[36–38]. A mid-treatment approach for plan adaptation
for centrally located thoracic tumors allowed reduction of
OAR violations and recovery of PTV coverage due to
interfractional changes [39].
In summary, MgRT offers improved accuracy of the
target position by means of superior intra-fraction tumor
visualization. MRgRT is expected to achieve prolonged
disease-free survival and lower toxicity for thoracic lung
tumors, especially in the field of re-irradiation and in the
management of centrally located lesions, by using better
intra-fraction motion management in combination with
online plan adaptation.
Breast
The standard of care for patients with early breast can-
cer after breast conserving surgery is whole breast irradi-
ation [40, 41]. Recently, new treatment approaches using
partial breast irradiation (PBI) or accelerated partial
breast irradiation (APBI) in low-risk tumors were ana-
lyzed [42]. PBI aims to reduce irradiated breast volume
in order to decrease long-term side-effects of treatments,
optimizing cosmetic outcomes and improving quality of
life while maintaining local tumor control [43]. Never-
theless, conflicting results concerning toxicity and cos-
metic outcome have been reported [44, 45].
A possible concern of the inconclusive data are differ-
ences in target volume delineation, the dosimetric charac-
teristics and the dose-fractionation schedules of the various
APBI techniques. Localization and delineation of the CTV
on a postoperative CT remains difficult, even if additional
clips are placed in the tumor bed. Furthermore, additional
margins must be added to the CTV to account for chest
wall movement and patient set-up in External Beam RT
(EBRT), which may result in larger irradiated volumes in
EBRT compared to brachytherapy or intra-operative APBI
techniques [46, 47]. The challenge of adequate target defi-
nition in postoperative RT could be mastered with MRgRT,
as MRI has excellent soft-tissue contrast, especially in the
visualization of irregularities and spiculations [48].
Another approach could be the preoperative MRgRT
APBI. Preoperative target delineation showed to have
less inter-observer variation as compared to the post-
operative setting [49, 50]. MRI has a high sensitivity for
detection of invasive breast cancer and a good corre-
lation with histopathology findings [48]. To date, diffe-
rent groups evaluated the concept of single dose APBI
delivered prior to surgical resection and treated the first
patients [51, 52]. Horton et al. [52] designed a phase I
dose escalation trial of a single-dose preoperative ra-
diation treatment for early stage breast cancer patients
(node-negative, invasive breast cancer or DCIS ≤2 cm).
There were three different dose escalation levels of 15
Gy (n = 8), 18 Gy (n = 8) or 21 Gy (n = 16) and lumpec-
tomy was performed within 10 days. The CTV was
delineated using a planning MRI, and included the GTV
with an isotropic margin of 15 mm. Overall, no acute
dose-limiting grade 3 radiation-related toxicities were
reported. These early results seem encouraging and
represent a first step toward a novel APBI approach [52].
In summary, set-up margins can be further reduced, as
no co-registration of planning MRI and CT is required
and dose delivery can be performed using respiratory
gated MRgRT. This approach can reduce irradiated
breast volume and therefore normal tissue toxicity, as
cardiac toxicity [53, 54]. Moreover, MR-guided preopera-
tive RT could potentially facilitate dose escalation and
enable an ablative, definitive treatment approach for
early-stage breast cancer. Obviously, the MRgRT
approach for breast cancer needs to be tested in further
clinical trials, but it already appears to have the potential
to become a future “game changer” in the portfolio of
individualized breast RT strategies.
Gastrointestinal tumors
Liver
Liver represents an intriguing anatomic site of applica-
tion for MRgRT SBRT due to the increasing utilization
of MRI in the characterization of primary and secondary
hepatic lesions and the emergent role of SBRT in their
management [55, 56]. Kishan et al. [57] evaluated the
dosimetric feasibility of Tri-Cobalt-60 MR-guided RT
liver SBRT and observed optimal liver and kidney
sparing, especially for the most peripheral lesions.
Furthermore, MRI real-time 2-Dimension gating imaging
can efficaciously manage treatment volumes movements
through direct and/or indirect gating approaches and over-
come the necessity of invasive fiducials implantation [58].
Despite the promising technical solutions, the clinical
evidence about liver MRgRT still remains anecdotal [59].
Pancreas
The anatomical characteristics and location of the pancreas
make it difficult to find the balance between target
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coverage and OAR sparing, especially in the SBRT setting.
Available technologies for patient re-positioning and dose
delivery (CBCT, motion management solutions) do not
allow effective dose escalation of the target and toxicity
remains a strong dose-limiting factor [60–66].
Various studies have described the segmentation
advantages and planning solutions for MRgRT in this
scenario; in particular, its online adaptive approach,
which appears suitable for dose escalation, plan adapta-
tion and inter-fraction anatomical variability manage-
ment [59, 67, 68]. Larger studies are needed to evaluate
the occurrence of toxicity with this approach. Neverthe-
less, the first clinical results on a very limited number of
patients seem promising [59, 69]. For these reasons,
pancreatic cancer represents one of the most important
applications of MR-guided RT and is a good candidate
for further developments of online adaptive solutions.
Rectum
To date, MRI represents the gold standard technique in
rectal cancer diagnosis, due to its excellent soft tissue
contrast and high spatial resolution. The integration of
this kind of imaging in hybrid MRgRT solutions opens
up new frontiers for segmentation and dose escalation
protocols [70]. Further advantages will come from the
use of specific MRI sequences, such as diffusion
weighted imaging (DWI), and radiomics applications
throughout the course of RT treatment to identify new
target volumes and assess or predict response [71, 72].
Clinical studies on rectal cancer MRgRT are not yet
available in literature, but its feasibility and safety in the
neoadjuvant setting have been evaluated. Treatment
plans of the Tri-60-Co MRL systems reach comparable
target coverage, although larger volumes of OARs (i.e.
small bowel) receive higher low-moderate doses as com-
pared to standard intensity-modulated RT technologies
[73]. These results encourage MRgRT applications with
higher energy systems (MRL) on large rectal cancer
patient cohorts.
Urogenital tumors
Kidney
Although renal cell carcinoma (RCC) has historically
been considered a radioresistant entity, and RT has been
usually applied with palliative intent, recent techno-
logical advancements are allowing radiation oncologists
to introduce RT with a curative intent also in this
setting. Ongoing studies confirming the safety and efficacy
of preliminary reported data are likely to open a scenario,
in the near future, that integrates SBRT into the thera-
peutic algorithm of primary RCC [74, 75].
Nevertheless, the kidney is affected by large intra-fraction
respiratory variations that can dramatically change during
the treatment of daily fractionation [76–80]. Stemkens et al.
[81] developed a calculation method to evaluate the accu-
mulated dose for MR-guided SBRT of RCC in case of
intra-fraction respiratory modifications, determining
the effect of such uncertainties on the deposited dose.
In their small patient cohort, these variations showed
large dosimetric differences with respect to the planned
dose distribution, confirming the potential role of on-
line MR-guidance combined with real-time treatment
planning adaptation during daily SBRT delivery for
RCC. Moreover, Stam and colleagues showed that the
dosimetric feasibility of MRgRT was strictly related to
the geometry of the affected kidney, the dimension of the
target and the proximity of the bowel during the daily on-
line evaluation. A maximum diameter of the kidney lesion
of 35mm was considered the cut-off for a safe treatment
without violation of the OAR constraints [82].
In summary, considering the previous discussed un-
certainties related to respiratory variations and the indi-
vidual anatomy conformation of the region of interests,
kidney tumor irradiation by MRL seems promising.
MRgRT for primary and metastatic tumors in the kidney
may represent a new tool to expand its therapeutic
application in the near future, although it is still under
development due to the paucity of available clinical data.
Prostate
RT has a well-defined role in the management of organ-
confined prostate cancer and is considered a standard
curative treatment option, especially in the era of dose
escalation and hypofractionation by IMRT and IGRT, and
more recently by means of SBRT [83]. Despite the
routinely adoption of daily IGRT to compensate for inter-
fractional variations, the intra-fractional motion of the
prostate gland and OARs [84, 85] during irradiation con-
tinues to be challenging [86]. Peng et al. [87] showed that,
when the baseline treatment plan is superimposed on
daily CBCT scans, about one third of the sessions would
require an online plan adaptation due to the differences
between planned and delivered dose to the prostate target
and OARs. Obviously, these discrepancies become more
relevant when ultra-fractionated schedules are adopted
[88]. MR-guided image guidance can offer improved
anatomical definition compared to on-board CBCT [89]
while reducing radiation exposure. Furthermore, real-time
MR imaging during dose delivery is able to take into
account not only the systematic anatomical variability of
prostate swelling, but also random anatomical changes,
such as inter/intra-fraction bladder and rectal filling, as
well as independent variations and deformations of OARs.
In fact, the most interesting benefit in prostate cancer
RT is undoubtedly represented by the ability to perform
daily adaptive replanning. With conventional IGRT, there
are no possibilities to compensate for the independent
movements of the prostate volume. At the beginning of
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the treatment, RT can induce a volumetric increase of the
prostate gland followed by a decrease towards the end of
the treatment [84]. In case of extreme hypofractionated
schedules, the swelling may even persist after the end of
treatment [90]. Therefore, the online adaptive strategies
used by the MRL systems are likely to radically change the
management of prostate cancer RT. Furthermore, online
MR monitoring can automatically pause the treatment
delivery if the prostate position exceeds a predefined
threshold. Moreover, MRgRT enables to avoid specific
radio-opaque markers that serve as a surrogate for the
prostate position. Another clinical value that advocates
MRgRT in prostate cancer is the role of predicting treat-
ment response [91]. Specific MRI sequences could be used
as an indicator for early tumor response, as confirmed by
preliminary data on diffusion weighted imaging (DWI)
during MRL delivery [91].
In summary, the recent developments of MRgRT
systems open up new perspectives for RT in prostate can-
cer by enabling adaptive and on-line tracking strategies,
especially when extremely high doses per fraction are
prescribed. Furthermore, the capability to produce high
quality MR sequences during and after the treatment, will
probably further change the perspective of the MRI avail-
ability in this setting, opening an unexplored window on
the landscape of radiomics for prostate cancer RT.
Bladder
Radical cystectomy and RT (with or without chemother-
apy), are the two main treatment approaches for muscle-
invasive bladder cancer [92]. Historically, RT has been
reserved for patients with inoperable bladder tumors or
when defined as medically unfit for cystectomy. A grow-
ing amount of evidence suggests that tri-modality treat-
ment for bladder preservation is potentially able to
obtain acceptable outcomes and can be considered a
treatment option in selected patients [93, 94]. The tri-
modality approach includes transurethral resection of
the bladder cancer lesion followed by RT and concomi-
tant chemotherapy.
However, one of the main criticisms regarding RT in
bladder cancer is related to organ motion management.
The bladder is a hollow mobile organ, seriously affected
by changes in size and position during RT. This can
dramatically impact daily dose coverage of the bladder
tumor and OARs sparing, limiting the reliability and
reproducibility of the entire RT [95–102]. To overcome
this issue, large margins surrounding the target region
are usually applied. Nevertheless, larger margins used to
compensate uncertainties in treatment volume, result in
increased toxicity [103, 104].
In order to check and correct the position, size and
shape of the bladder for each treatment fraction, a high
quality 3D image acquisition using CBCT has been
introduced in clinical practice [105, 106]. Vestergaard and
colleagues [107] tried to assess the optimal bladder target
coverage by online MR-guided adaptive re-optimization
using three kinds of margins: isotropic, anisotropic, and
population-based. All three MR-guided adaptive strategies
were able to obtain a large reduction in target volumes
compared to a plan library approach. More specifically,
the anisotropic margin resulted in the largest advantage in
terms of PTV minimization [107]. This experience
confirmed the promising role of MRL systems for
online target shift check and correction during a treat-
ment fraction for bladder cancer.
In summary, although some concerns remain in regard
to the additional time needed to carry out online dose
distribution re-optimization, the advent of MRL systems
will undoubtedly improve bladder cancer adaptive RT
strategies, reinforcing its indication in this setting [108].
Gynecological tumors
Standard therapy for locally advanced cervical cancer is
a combination of concurrent chemo-RT followed by
brachytherapy [109]. Despite the wide application of
daily image-guidance and advanced RT techniques
including IMRT and VMAT, long-term urogenital and
gastrointestinal side-effects are still frequent [110].
Due to its excellent soft-tissue contrast, MRI is already
widely applied for staging and post-treatment evaluation
of cervical cancer, as it is superior in assessing tumor
size as well as soft tissue invasion compared to conven-
tional CT imaging [111, 112]. However, regarding
image-guidance, CBCT is still routinely used in RT,
while MRI is recommended as the imaging method of
choice for brachytherapy [113]. MR-guided brachyther-
apy is gradually becoming standard of care by allowing
superior sparing of surrounding radiosensitive organs
combined with dose escalation compared to con-
ventional 2D-planning [114–117]. Based on the excellent
results of MR-guidance in brachytherapy, it has been
questioned for EBRT of cervical cancer, whether MRI
could not only be applied for advanced tumor delineation
but also for image-guidance [110, 114, 118]. The CTV for
EBRT comprises the cervix and the uterus which are
known to show significant inter- and intra-fractional
motion due to the close proximity to hollow OARs
[110, 119]. Large safety margins are usually needed in
CBCT-imaged-guided RT to account for random and
patient-specific organ movement [110, 119]. Due to the po-
tential regression of cervical cancer of up to 60–80% of the
pre-therapeutic tumor volume during EBRT, further pelvic
organ motion might be expected during RT [118, 120].
MRgRT with its superior soft-tissue contrast allowing
for precise and immediate detection of inter-fractional
organ motion as well as tumor shrinkage in response to
therapy includes the potential of reducing toxicity and
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potentiating dose escalation in EBRT for cervical cancer
[110, 121]. Furthermore, functional MRI comprising
non-invasive assessment of tissue perfusion, hypoxia or
cellular density might be applied to guide RT treatment
in cervical cancer with e.g. higher doses delivered to
hypoxic tumor parts [110, 122–127]. While first shuttle-
based approaches have shown that offline MRgRT is
feasible for cervical cancer, the high potential of the new
hybrid MRL devices is an immediate online adaptive
treatment based on the anatomy of the day [3, 128–132].
Additionally, due to intra-fractional imaging, advanced
motion management strategies, like gating become pos-
sible providing a “real-time” anatomical feedback with
the advantage of further reducing safety margins [121].
A first case report about both, MR-guided EBRT and
brachytherapy underlined the high potential of this new
promising technique for cervical cancer [132].
In summary, MRg RT for cervical cancer can represent
a promising tool to overcome the limits of conventional
IGRT systems, in order to improve daily adaptive RT stra-
tegies. Further studies can confirm its potential disruptive
role in this setting.
Oligometastatic disease
Metastatic solid cancer was long considered incurable and
treatment consisted mainly of palliative chemotherapy.
Local treatments, such as surgery or radiotherapy, with
palliative, non-ablative doses were restricted to symptom
control. The concept of oligometastatic disease (OMD) is
currently challenging this dogma by defining an inter-
mediate state of metastasized disease, with a more favor-
able disease biology and dynamic. OMD is characterized
by a limited number of metastatic lesions and a low
overall metastatic burden that opens a therapeutic window
for radical treatment to all metastatic sites. Originally
coined by Hellman and Weichselbaum in 1995 [133], the
idea has gained traction particularly during recent years
through several developments: a) improved diagnostics for
early detection of low disease burden b) clinical imple-
mentation of minimally invasive and high-precision
locally-ablative treatments (LAT) such as video- or robotic
assisted surgery (VATS, RATS) or SBRT c) more effective
systemic treatments that have led to a prolonged overall
survival (OS) of metastatic patients and d) a better
biological and clinical understanding of tumor biology.
In the treatment of oligometastatic disease, early efforts
have mainly focused on the radical treatment of readily
resectable lesions, like brain and adrenal metastases. With
the improvement in diagnostic imaging and novel devel-
opments in non-invasive LAT modalities such as SBRT,
prospective reports have surfaced recently that investigate
radical treatment of all disease sites, potentially leading to
improved clinical outcome [134–136]. Still, a major con-
cern is the potential toxicity from high local ablative
radiotherapy dose, especially in anatomical regions not
readily visualized with current IGRT methods (proximal
bronchial tree, esophagus, duodenum, small and large
bowel). The advent of MRgRT and the possibility to
instantly adapt the RT dose to the daily anatomical
situations open a window of opportunity to deliver high
radiation doses while sparing surrounding normal tissue
on a daily basis. In principle, all anatomical locations can
be targeted in this way and most thoracic and abdominal
indications have already been mentioned in this review.
Therefore, we will focus our discussion on the advantages
of MRgRT to the following clinical scenarios:
Lymph node metastases
In a recent review on SBRT for lymph node (LN) metas-
tases, Jereczek-Fossa et al. reported local control rates of
64% up to 98% at 3 years [137]. A clear dose response
correlation was observed as well. One of the latest
reports could also correlate local control with overall
survival [138]. Therefore, there is a relevant need to
locally apply a sufficient dose in order to improve
outcome. Depending on the visibility of lymph nodes in
CBCT, this is difficult to achieve in certain cases and
may even necessitate larger PTV margins to a certain
proper targeting. A first MRI-guided planning approach
to investigate the benefits of direct tumor visualization,
margin reduction and improvement in dose delivery to
OAR has been reported [139]. This technology improve-
ment for better dose delivery is timely, as the interest in
LN targeting especially in prostate cancer is becoming
critical due to the outstanding detection rate of small
LN metastases in PSMA PET [140]. As these targets are
small, difficult to detect in CBCT, online MR-guidance
is ideally suited to treat these lesions. It remains to be
seen whether the first positive results of such an ap-
proach will translate into a durable clinical benefit [141].
Adrenal gland metastases
In the oligometastatic setting, radical treatment of ad-
renal metastases in the form of surgical resection is a
well-established indication. Reports on CT guided
SBRT have emerged with very encouraging local response
rates, as long as the tumors can be readily visualized and a
sufficient ablative radiation dose can be delivered
[142, 143]. Local control rates of 32 to 90% have been
reported with varying fractionation schedules. It is
not surprising that this tumor site has been identified
as a promising target for MRgRT, as more reliable
visualization with online mitigation of tumor motion
is possible. A first clinical report on MR-guided SBRT
of adrenal glands showed significant inter-fraction dis-
placements of OAR and the dosimetric benefit of online
plan adaptation which resulted in consistently delivery of
high radiation doses [37].
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Conclusions
In summary, MRgRT can be considered a groundbreaking
new technology that is capable of creating new perspec-
tives towards an individualized, patient-oriented planning
and treatment approach, especially due to the ability to
use daily online adaptation strategies. Furthermore, MRL
systems overcome the limitations of conventional IGRT,
especially in soft tissue, where target and OARs need
accurate definition. Nevertheless, some concerns remain
concerning the additional time needed to re-optimize dose
distributions online, the reliability of the gating and
tracking procedures and the interpretation of functional
MR imaging markers and their potential changes during
the course of treatment. Due to its continuous tech-
nological improvement and rapid clinical large-scale appli-
cation in several anatomical settings, further studies may
confirm the potential disruptive role of MRgRT in the
evolving oncological environment.
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